ADX71943

**ADX71943** is an orally available small molecule positive allosteric modulator (PAM) of the **GABA_B receptor**, developed by **Addex Pharmaceuticals** using their proprietary allosteric modulator platform. It enhances GABA_B receptor potency and efficacy in the presence of GABA, demonstrating analgesic effects in preclinical models of osteoarthritis pain (e.g., CFA, formalin, monosodium iodoacetate), chronic nociceptive pain, and visceral pain, with minimum effective oral doses of 3-10 mg/kg. Unlike orthosteric agonists like baclofen, which cause tolerance and CNS side effects (sedation, memory impairment), ADX71943 has a differentiated profile potentially avoiding these issues due to its peripherally restricted activity, making it suitable for long-term treatment of chronic pain conditions like osteoarthritis, where current options (NSAIDs, opioids) have poor side effect profiles.

Other names

ADX-71743ADX71743ADX 71743